XBiotech Inc. (XBIT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

XBiotech Inc. (XBIT) Healthcare & Pipeline Overview

XBiotech Inc., a biopharmaceutical company, develops True Human monoclonal antibodies for inflammatory and infectious diseases. Their focus on interleukin-1 alpha therapies positions them in the competitive biotechnology sector, targeting conditions like cancer, stroke, and arthritis. The company operates from its headquarters in Austin, Texas.

What Is the Investment Thesis for XBIT?

XBiotech Inc. presents a focused investment opportunity within the biotechnology sector, centered on its True Human monoclonal antibody platform. The company's pipeline, targeting inflammatory and infectious diseases, holds potential for significant growth, particularly through its interleukin-1 alpha (IL-1α) therapies. These therapies aim to address conditions like cancer, stroke, and arthritis, where IL-1α plays a critical role. A key value driver is the successful development and commercialization of these therapies, contingent on positive clinical trial outcomes and regulatory approvals. The company's market capitalization is approximately $0.07 billion, reflecting both the potential and the risks associated with its developmental stage. Upcoming clinical trial results will likely serve as major catalysts. However, the company faces risks related to clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

XBIT Key Highlights

XBiotech Inc. focuses on True Human monoclonal antibodies for treating various diseases.

• The company's pipeline targets both inflammatory and infectious diseases.
• XBiotech is developing interleukin-1 alpha therapies for conditions like cancer, stroke, heart attack, and arthritis.
• The company is also developing True Human COVID-19 therapy for treating the COVID-19 mutant virus.
• XBiotech Inc. was incorporated in 2005 and is headquartered in Austin, Texas.

Who Are XBIT's Competitors?

XBIT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are XBIT's Key Strengths?

Proprietary True Human monoclonal antibody platform

• Focus on interleukin-1 alpha (IL-1α) therapies
• Potential for therapies targeting unmet medical needs
• Experienced management team

What Are XBIT's Weaknesses?

Limited financial resources

• Dependence on successful clinical trial outcomes
• Small number of employees
• Limited commercialization experience

What Could Drive XBIT Stock Higher?

Clinical trial results for interleukin-1 alpha (IL-1α) therapies in cancer treatment.

• Regulatory submissions for True Human COVID-19 therapy.
• Expansion of strategic partnerships and collaborations.
• Advancements in the True Human antibody platform.

What Are the Key Risks for XBIT?

Negative return on equity (-31.6%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $5.7M recently.
• Clinical trial failures for key therapeutic candidates.
• Regulatory delays or rejections for new therapies.
• Competition from established pharmaceutical companies.
• Dependence on limited financial resources.
• Patent expiration and intellectual property challenges.

What Are the Growth Opportunities for XBIT?

• Development of Interleukin-1 Alpha (IL-1α) Therapies: XBiotech's focus on IL-1α therapies presents a significant growth opportunity. IL-1α is a key mediator of inflammation and tissue breakdown, implicated in various diseases such as cancer, stroke, heart attack, and arthritis. Successful development and commercialization of these therapies could address a substantial market need, potentially generating significant revenue.
• Expansion of True Human Antibody Platform: XBiotech's True Human antibody platform offers a versatile foundation for developing therapies against a wide range of diseases. By expanding this platform and identifying new antibody targets, XBiotech can create a pipeline of novel therapeutic candidates. This approach allows for diversification of the company's product portfolio and reduces reliance on a single therapeutic area. The market for antibody-based therapies is projected to continue growing, driven by their specificity and efficacy.
• Strategic Partnerships and Collaborations: XBiotech can pursue strategic partnerships and collaborations with other biotechnology and pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships can provide access to additional funding, expertise, and resources, enhancing XBiotech's capabilities and expanding its market reach. Collaborations can also facilitate the entry into new therapeutic areas and geographic markets, contributing to long-term growth.
• Advancement of COVID-19 Therapy: The development of a True Human COVID-19 therapy targeting mutant viruses presents a timely growth opportunity. As the COVID-19 pandemic continues to evolve, new variants emerge, necessitating the development of effective treatments. XBiotech's therapy has the potential to address this ongoing need, providing a valuable tool in the fight against the virus. The market for COVID-19 therapies remains significant, offering a potential revenue stream for XBiotech.
• Geographic Expansion: XBiotech can expand its geographic presence by entering new markets and establishing distribution networks. This expansion can increase the company's revenue base and reduce its dependence on a single geographic region. Emerging markets, in particular, offer significant growth potential due to their increasing healthcare spending and unmet medical needs. Successful geographic expansion requires careful planning and execution, including regulatory approvals and market access strategies.

What Are XBIT's Competitive Advantages?

• Proprietary True Human monoclonal antibody platform.
• Pipeline of product candidates targeting unmet medical needs.
• Expertise in developing therapies for inflammatory and infectious diseases.

What Does XBIT Do?

XBiotech Inc., established in 2005 and headquartered in Austin, Texas, is a biopharmaceutical company dedicated to discovering, developing, and commercializing True Human monoclonal antibodies. These antibodies are designed for treating a range of diseases, with a primary focus on inflammatory and infectious conditions. The company's core strategy revolves around creating a pipeline of product candidates that address unmet medical needs in various therapeutic areas. XBiotech's lead programs center on interleukin-1 alpha (IL-1α) therapies. IL-1α is a potent mediator of inflammation and tissue breakdown, playing a significant role in diseases such as cancer, stroke, heart attack, and arthritis. By targeting IL-1α, XBiotech aims to develop treatments that can reduce inflammation, prevent tissue damage, and improve patient outcomes. Their pipeline also includes True Human COVID-19 therapy, targeting the COVID-19 mutant virus. Since its inception, XBiotech has focused on leveraging its True Human antibody platform to create therapies that are both effective and well-tolerated. The company's approach involves identifying and isolating naturally occurring human antibodies that have the potential to neutralize disease-causing targets. These antibodies are then developed into therapeutic candidates for clinical testing and potential commercialization. XBiotech's commitment to innovation and its focus on True Human antibodies differentiate it in the competitive biotechnology landscape.

What Products and Services Does XBIT Offer?

• Discovers True Human monoclonal antibodies.
• Develops True Human monoclonal antibodies for treating various diseases.
• Commercializes True Human monoclonal antibodies.
• Focuses on therapies for inflammatory diseases.
• Develops therapies for infectious diseases.
• Targets interleukin-1 alpha to treat medical conditions.
• Develops True Human COVID-19 therapy for treating the COVID-19 mutant virus.

How Does XBIT Make Money?

• Discovers and develops True Human monoclonal antibodies.
• Out-licenses or sells developed therapies to pharmaceutical companies.
• Generates revenue through research grants and collaborations.

What Industry Does XBIT Operate In?

XBiotech Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for monoclonal antibody therapies is substantial, driven by the increasing prevalence of chronic diseases and advancements in biotechnology. Companies like XBiotech face the challenge of navigating complex regulatory pathways, securing funding for research and development, and competing with larger, more established pharmaceutical companies. The biotechnology industry is experiencing growth, fueled by technological advancements and increasing investment in healthcare.

Who Are XBIT's Key Customers?

• Pharmaceutical companies seeking novel therapies.
• Patients suffering from inflammatory diseases.
• Patients suffering from infectious diseases.

The most recent 6 insider filings for XBiotech Inc. break down as 1 sales and 5 purchases. On net that is roughly 1.2M shares disposed (about $5.7M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: XBiotech Inc.

Revenue for XBiotech Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $6.7M, with diluted EPS of $-0.22. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, XBIT averaged $-0.37 in diluted EPS.

XBIT Valuation & Market Position

With a $66.2M market cap, XBiotech Inc. sits in the micro-cap segment of the market. Relative to its peer group, XBIT's quantitative score of 51/100 is below the peer average of 76/100.

Return on equity for XBiotech Inc. stands at -31.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -33.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -62.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 33.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -68.5%, the inverse of the P/E and a quick read on earnings relative to price.

XBiotech Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.00 places it in the safe zone, indicating low near-term bankruptcy risk.

XBiotech Inc. has missed Wall Street's EPS estimate in 3 of its last 3 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 1277.8% below estimates on average.

Company Profile

XBiotech Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Sushma Shivaswamy. XBIT has traded publicly since 2015.

XBIT Financials

XBIT Latest News

XBIT Analyst Consensus

XBIT MoonshotScore

What Investors Ask About XBiotech Inc. (XBIT) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources